Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Bacterial Vaginosis
- Main trialPhase 1
- “Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).”In the company’s words, NCT05354050 on ClinicalTrials.gov
Other drugs for Bacterial Vaginosis
- BPR-101Chengdu Syncor Pharmaceutical Co., Ltd. · Phase 2
- FB-301Freya Biosciences ApS · Phase 2
- WST03 Vaginal MetronidazoleSPH Sine Pharmaceutical Laboratories Co., Ltd. · Phase 2
- GenSci142Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 18 Nov 2020 | Pharmacokinetic Study of DARE-BV1 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026